ABSTRACT (updated)

DART (Development of Second-line Therapy) in Africa is a randomized controlled trial comparing laboratory and clinical (CD4) versus clinical monitoring only (CMO) in 3316 previously untreated symptomatic HIV-1 infected patients initiating ART with CD4 <200 cells/mm3 in Uganda (2 sites) plus 1 site site and Zimbabwe (1 site).

AIM

To compare immunological responses to boosted PI-containing second-line versus non-PI-containing first-line regimens in adults initiating ART with low CD4 counts in the DART trial, and switching according to immunological/clinical criteria.

IMMUNOLOGICAL RESPONSES

Figure 1 Response to first and second line

- median (IQR) absolute CD4 count over time from initiation of first-line or second-line ART

- Linear mixed effect model estimates with 95% CI

RESULTS - switch to second-line

- 495 (15%) patients who switched to second-line had sufficient opportunity to respond immunologically to first-line, in whom we were uncertain whether such patients would respond at all to second-line.

CONCLUSIONS

- Immunological response to bPI (LPV/r) containing second-line after the first line failure is comparable to response to first-line in patients with low CD4 counts in Africa.

- DART is funded by the UK Department for International Development (DFID) and GlaxoSmithKline, Gilead Sciences.

- We thank all the patients and staff from all the centres participating in the DART trial.

- The ABSTRACT (updated) was presented at 13th Conference on Retroviruses and Opportunistic Infections, Nice, France, March 3-6, 2016.

- The ABSTRACT (updated) was presented at the 12th Conference on Retroviruses and Opportunistic Infections, Seattle, USA, February 21-24, 2015.

- The ABSTRACT (updated) was presented at the 11th Conference on Retroviruses and Opportunistic Infections, Pittsburgh, USA, February 24-27, 2014.

- The ABSTRACT (updated) was presented at the 10th Conference on Retroviruses and Opportunistic Infections, Washington, USA, February 5-8, 2013.

- The ABSTRACT (updated) was presented at the 9th Conference on Retroviruses and Opportunistic Infections, Boston, USA, February 26-29, 2012.

- The ABSTRACT (updated) was presented at the 8th Conference on Retroviruses and Opportunistic Infections, San Francisco, USA, February 27-30, 2011.

- The ABSTRACT (updated) was presented at the 7th Conference on Retroviruses and Opportunistic Infections, Seattle, USA, February 28-March 1, 2010.

- The ABSTRACT (updated) was presented at the 6th Conference on Retroviruses and Opportunistic Infections, Denver, USA, February 22-25, 2009.

- The ABSTRACT (updated) was presented at the 5th Conference on Retroviruses and Opportunistic Infections, Seattle, USA, February 25-28, 2008.

- The ABSTRACT (updated) was presented at the 4th Conference on Retroviruses and Opportunistic Infections, San Diego, USA, February 18-21, 2007.

- The ABSTRACT (updated) was presented at the 3rd Conference on Retroviruses and Opportunistic Infections, San Francisco, USA, February 13-16, 2006.

- The ABSTRACT (updated) was presented at the 2nd Conference on Retroviruses and Opportunistic Infections, Boston, USA, February 12-15, 2005.

- The ABSTRACT (updated) was presented at the 1st Conference on Retroviruses and Opportunistic Infections, Washington, USA, February 14-17, 2004.

- The ABSTRACT (updated) was presented at the 9th Conference on Retroviruses and Opportunistic Infections, Boston, USA, February 26-29, 2012.

- The ABSTRACT (updated) was presented at the 8th Conference on Retroviruses and Opportunistic Infections, Seattle, USA, February 27-30, 2011.

- The ABSTRACT (updated) was presented at the 7th Conference on Retroviruses and Opportunistic Infections, Seattle, USA, February 28-March 1, 2010.

- The ABSTRACT (updated) was presented at the 6th Conference on Retroviruses and Opportunistic Infections, Denver, USA, February 22-25, 2009.

- The ABSTRACT (updated) was presented at the 5th Conference on Retroviruses and Opportunistic Infections, Seattle, USA, February 25-28, 2008.

- The ABSTRACT (updated) was presented at the 4th Conference on Retroviruses and Opportunistic Infections, San Diego, USA, February 18-21, 2007.

- The ABSTRACT (updated) was presented at the 3rd Conference on Retroviruses and Opportunistic Infections, San Francisco, USA, February 13-16, 2006.

- The ABSTRACT (updated) was presented at the 2nd Conference on Retroviruses and Opportunistic Infections, Boston, USA, February 12-15, 2005.

- The ABSTRACT (updated) was presented at the 1st Conference on Retroviruses and Opportunistic Infections, Washington, USA, February 14-17, 2004.

- The ABSTRACT (updated) was presented at the 9th Conference on Retroviruses and Opportunistic Infections, Boston, USA, February 26-29, 2012.

- The ABSTRACT (updated) was presented at the 8th Conference on Retroviruses and Opportunistic Infections, Seattle, USA, February 27-30, 2011.

- The ABSTRACT (updated) was presented at the 7th Conference on Retroviruses and Opportunistic Infections, Seattle, USA, February 28-March 1, 2010.

- The ABSTRACT (updated) was presented at the 6th Conference on Retroviruses and Opportunistic Infections, Denver, USA, February 22-25, 2009.

- The ABSTRACT (updated) was presented at the 5th Conference on Retroviruses and Opportunistic Infections, Seattle, USA, February 25-28, 2008.

- The ABSTRACT (updated) was presented at the 4th Conference on Retroviruses and Opportunistic Infections, San Diego, USA, February 18-21, 2007.

- The ABSTRACT (updated) was presented at the 3rd Conference on Retroviruses and Opportunistic Infections, San Francisco, USA, February 13-16, 2006.

- The ABSTRACT (updated) was presented at the 2nd Conference on Retroviruses and Opportunistic Infections, Boston, USA, February 12-15, 2005.

- The ABSTRACT (updated) was presented at the 1st Conference on Retroviruses and Opportunistic Infections, Washington, USA, February 14-17, 2004.